Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.
The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients.
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.
Teaching NeuroImages: MRI in advanced neuromyelitis optica.
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-N-acetylgalactosaminyl-GD1a antibody.
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Risk factors for rare diseases can be risky to define: PML and natalizumab.
The multiple sclerosis rating scale, revised (MSRS-R): Development, refinement, and psychometric validation using an online community.
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Disease-modifying treatments for progressive multiple sclerosis.
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.
A high-density screen for linkage in multiple sclerosis.
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
Overcoming barriers in progressive multiple sclerosis research.
Saccadic intrusions: review and update.
Sanofi withdraws Campath in US and EU
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia

Pages